Cargando…

Identifying problematic drugs based on the characteristics of their targets

Identifying promising compounds during the early stages of drug development is a major challenge for both academia and the pharmaceutical industry. The difficulties are even more pronounced when we consider multi-target pharmacology, where the compounds often target more than one protein, or multipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopes, Tiago J. S., Shoemaker, Jason E., Matsuoka, Yukiko, Kawaoka, Yoshihiro, Kitano, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555035/
https://www.ncbi.nlm.nih.gov/pubmed/26388775
http://dx.doi.org/10.3389/fphar.2015.00186
_version_ 1782388119578869760
author Lopes, Tiago J. S.
Shoemaker, Jason E.
Matsuoka, Yukiko
Kawaoka, Yoshihiro
Kitano, Hiroaki
author_facet Lopes, Tiago J. S.
Shoemaker, Jason E.
Matsuoka, Yukiko
Kawaoka, Yoshihiro
Kitano, Hiroaki
author_sort Lopes, Tiago J. S.
collection PubMed
description Identifying promising compounds during the early stages of drug development is a major challenge for both academia and the pharmaceutical industry. The difficulties are even more pronounced when we consider multi-target pharmacology, where the compounds often target more than one protein, or multiple compounds are used together. Here, we address this problem by using machine learning and network analysis to process sequence and interaction data from human proteins to identify promising compounds. We used this strategy to identify properties that make certain proteins more likely to cause harmful effects when targeted; such proteins usually have domains commonly found throughout the human proteome. Additionally, since currently marketed drugs hit multiple targets simultaneously, we combined the information from individual proteins to devise a score that quantifies the likelihood of a compound being harmful to humans. This approach enabled us to distinguish between approved and problematic drugs with an accuracy of 60–70%. Moreover, our approach can be applied as soon as candidate drugs are available, as demonstrated with predictions for more than 5000 experimental drugs. These resources are available at http://sourceforge.net/projects/psin/.
format Online
Article
Text
id pubmed-4555035
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-45550352015-09-18 Identifying problematic drugs based on the characteristics of their targets Lopes, Tiago J. S. Shoemaker, Jason E. Matsuoka, Yukiko Kawaoka, Yoshihiro Kitano, Hiroaki Front Pharmacol Pharmacology Identifying promising compounds during the early stages of drug development is a major challenge for both academia and the pharmaceutical industry. The difficulties are even more pronounced when we consider multi-target pharmacology, where the compounds often target more than one protein, or multiple compounds are used together. Here, we address this problem by using machine learning and network analysis to process sequence and interaction data from human proteins to identify promising compounds. We used this strategy to identify properties that make certain proteins more likely to cause harmful effects when targeted; such proteins usually have domains commonly found throughout the human proteome. Additionally, since currently marketed drugs hit multiple targets simultaneously, we combined the information from individual proteins to devise a score that quantifies the likelihood of a compound being harmful to humans. This approach enabled us to distinguish between approved and problematic drugs with an accuracy of 60–70%. Moreover, our approach can be applied as soon as candidate drugs are available, as demonstrated with predictions for more than 5000 experimental drugs. These resources are available at http://sourceforge.net/projects/psin/. Frontiers Media S.A. 2015-09-01 /pmc/articles/PMC4555035/ /pubmed/26388775 http://dx.doi.org/10.3389/fphar.2015.00186 Text en Copyright © 2015 Lopes, Shoemaker, Matsuoka, Kawaoka and Kitano. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lopes, Tiago J. S.
Shoemaker, Jason E.
Matsuoka, Yukiko
Kawaoka, Yoshihiro
Kitano, Hiroaki
Identifying problematic drugs based on the characteristics of their targets
title Identifying problematic drugs based on the characteristics of their targets
title_full Identifying problematic drugs based on the characteristics of their targets
title_fullStr Identifying problematic drugs based on the characteristics of their targets
title_full_unstemmed Identifying problematic drugs based on the characteristics of their targets
title_short Identifying problematic drugs based on the characteristics of their targets
title_sort identifying problematic drugs based on the characteristics of their targets
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555035/
https://www.ncbi.nlm.nih.gov/pubmed/26388775
http://dx.doi.org/10.3389/fphar.2015.00186
work_keys_str_mv AT lopestiagojs identifyingproblematicdrugsbasedonthecharacteristicsoftheirtargets
AT shoemakerjasone identifyingproblematicdrugsbasedonthecharacteristicsoftheirtargets
AT matsuokayukiko identifyingproblematicdrugsbasedonthecharacteristicsoftheirtargets
AT kawaokayoshihiro identifyingproblematicdrugsbasedonthecharacteristicsoftheirtargets
AT kitanohiroaki identifyingproblematicdrugsbasedonthecharacteristicsoftheirtargets